文献速递肝肾功能剂量调整特殊人群用药抗栓抗凝管理

基于暴露匹配的经肾排泄药物儿科剂量选择:直接口服抗凝药儿科开发的经验教训

Exposure Matching-Based Pediatric Dose Selection for Drugs with Renal Excretion - Lessons Learned from Pediatric Development of Direct Oral Anticoagulants.
PubMed 文献 · Clin Pharmacol Ther · 2024-08-13

本文以艾多沙班、利伐沙班、达比加群和接近完成的阿哌沙班四种直接口服抗凝药(DOACs)的儿科开发为例,总结经肾排泄药物儿科剂量选择的经验。四种DOACs的肾排泄占消除的27%或以上,导致儿童和成人受试者中年龄依赖性药物清除。教程分七步阐述从疾病与药物处置年龄差异到群体药代动力学模拟评估剂量调整的儿科剂量选择框架。

要点

  • 四种DOACs肾排泄占消除27%或以上,致年龄依赖性清除。
  • 儿科暴露匹配需先选参考成人人群与暴露水平。
  • 基于年轻成人数据预测儿科清除并选择剂量。

核心结论

  • 经肾排泄药物儿科剂量选择应基于暴露匹配,并系统考虑年龄相关差异与亚群剂量调整需求。

研究设计与样本

  • 本文为教程,以艾多沙班、利伐沙班、达比加群和阿哌沙班四种DOACs的儿科开发为案例。

主要发现

  • 四种DOACs的肾排泄占消除27%或以上,导致儿童和成人中年龄依赖性药物清除。

关键数值与推荐

  • 教程分七步:考虑年龄相关疾病与治疗反应差异、药物吸收分布代谢排泄差异、选择参考成人人群与暴露、基于年轻成人数据预测儿科清除与剂量、设计儿科PK/PD研究、用群体PK模拟评估暴露匹配与剂量调整、评估儿科亚群剂量调整需求。

临床怎么用

  • 临床药学可参照七步框架,对经肾排泄药物进行儿科暴露匹配与剂量选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The pediatric clinical development programs of the direct oral anticoagulants (DOACs) edoxaban, rivaroxaban, and dabigatran have recently been completed, with apixaban close to the finish line. One common pharmacokinetic (PK) characteristic of these four DOACs is that renal excretion contributes 27% or more in their elimination, resulting in age-dependent drug clearance in both pediatric and adult subjects. Several lessons have been learned from adult exposure matching and pediatric dose selection for DOACs. The main goal of this tutorial is to provide an informed perspective on pediatric dose selection for renally excreted drugs, using these four DOACs as case examples. This tutorial is organized into seven steps: (1) consideration of age-related differences in disease and response to treatment; (2) consideration of age-related differences in drug absorption, distribution, metabolism, and excretion; (3) selection of the reference adult population and exposure for pediatric exposure matching; (4) prediction of pediatric clearance and pediatric dose selection based on data from young adults; (5) conduct and design of efficient pediatric PK and pharmacodynamic (PD) studies that inform dose selection; (6) assessment of exposure matching and dose adjustment using population PK simulation; (7) evaluation of the need for dose adjustment in pediatric sub-populations.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Zou P, Leil TA. Exposure Matching-Based Pediatric Dose Selection for Drugs with Renal Excretion - Lessons Learned from Pediatric Development of Direct Oral Anticoagulants. Clin Pharmacol Ther. 2024. PMID: 39136405. doi:10.1002/cpt.3396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。